Navigation Links
Owner of Meningitis-Linked Pharmacy Declines to Testify Before Congress
Date:11/14/2012

By Steven Reinberg and Margaret Steele
HealthDay Reporters

WEDNESDAY, Nov. 14 (HealthDay News) -- The owner of the Massachusetts specialty pharmacy implicated in the meningitis outbreak that has killed 32 people declined to testify Wednesday before a Congressional committee investigating the matter, the Associated Press reported.

After a series of questions from members of the House Energy and Commerce Committee, Barry Cadden, co-founder of the New England Compounding Center, said: "Under advice of counsel, I respectfully decline to answer under basis of my constitutional rights and privileges, including the Fifth Amendment."

The committee hearing is focused on whether the outbreak, which has also sickened 438 people, could have been prevented.

Also expected to speak Wednesday is U.S. Food and Drug Administration Commissioner Margaret Hamburg. She is expected to tell the committee that new laws are needed to give her agency more legal authority and funding to oversee so-called compounding pharmacies, like the one in Massachusetts at the center of the deadly outbreak, the AP reported.

Compounding pharmacies combine, mix or alter ingredients to create drugs to meet the specific needs of individual patients. Such custom-made drugs may include a smaller dose, for example, or the removal of an ingredient that might trigger an allergy in a patient, according to the FDA.

Compounding pharmacies aren't subject to the same FDA oversight as regular drug manufacturers.

The New England Compounding Center in Framingham was the source of the tainted steroid injections, which are typically used for back and joint pain. The company has ceased operations since the meningitis outbreak first surfaced early last month.

Meningitis is inflammation of the lining surrounding the brain and spinal cord. Infected patients have developed a range of symptoms approximately one to four weeks following their injection.

On Thursday, Hamburg is scheduled to testify before the Senate Committee on Health, Education, Labor, and Pensions.

Last month, FDA investigators who toured the Framingham plant found foreign, "greenish-black" material in some vials of the injectable steroid suspected as the cause of the illnesses, federal health officials said. The contaminated product was one of a host of potential violations discovered during the recent inspection, the officials said.

"The investigators observed approximately 100 vials of the steroid drug, which purports to be a sterile injectable drug, that had a greenish-black foreign material and a white filamentous [containing filaments] material inside," Steven Lynn, director of the FDA's Office of Manufacturing and Product Quality, said during an Oct. 26 news conference.

In addition, the company couldn't prove that the equipment used to sterilize these products was actually able to sterilize them, Lynn said.

The FDA also found that the company wasn't able to keep its "clean room" clean, Lynn said. "A clean room is a space designed to maintain a controlled environment with low levels of airborne particles and surface contamination," he explained.

The U.S. Centers for Disease Control and Prevention on Friday had the following state-by-state breakdown of cases: Florida: 23 cases, including 3 deaths; Georgia, 1 case; Idaho, 1 case; Illinois, 2 cases; Indiana: 52 cases, including 4 deaths; Maryland: 23 cases, including 1 death; Michigan: 128 cases, including 7 deaths; Minnesota: 11 cases; New Hampshire: 13 cases; New Jersey: 27 cases; New York: 1 case; North Carolina: 3 cases, including 1 death; Ohio: 16 cases; Pennsylvania: 1 case; Rhode Island: 3 cases; South Carolina: 1 case; Tennessee: 81 cases, including 13 deaths; Texas: 2 cases; Virginia: 50 cases, including 2 deaths.

Ten of the 438 cases involve what the CDC calls "peripheral joint infection," meaning an infection in a knee, hip, shoulder or elbow. These joint infections aren't considered as dangerous as injections near the spine for back pain that have been linked to the potentially fatal meningitis infections.

The CDC and state health departments estimate that roughly 14,000 patients may have gotten steroid injections from the New England Compounding Center. All of the fungal meningitis patients identified so far were thought to be injected with the steroid methylprednisolone acetate, according to the CDC.

People who have had a steroid injection since July, and have any of the following symptoms, should talk to their doctor as soon as possible: worsening headache, fever, sensitivity to light, stiff neck, new weakness or numbness in any part of your body or slurred speech, the CDC said.

More information

The U.S. National Library of Medicine has more about injections for back pain.

SOURCES: Nov. 13, 2012, news release, U.S. Food and Drug Administration; Nov. 9, 2012, updated statistics, U.S. Centers for Disease Control and Prevention; Associated Press


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Chicago Dog Bite Injury Lawyers Advise Dog Owners To Get Control of Their Animals, Or Be Prepared To Pay Up
2. Chinese Drywall Complaint Center Now Demands Leadership From Obama & EPA, For Homeowners In Florida And In The US Southeast Stuck In Toxic Chinese Drywall Hell-Forward?
3. Lax gun ownership laws could impact ability of high-risk individuals to purchase firearms
4. Oxford University Press acquires joint ownership of Journal of Surgical Case Reports
5. Allergies May Plague Renters More Than Homeowners
6. Company With Links to Meningitis-Linked Pharmacy Recalls All Products
7. Company With Ties to Meningitis-Linked Pharmacy Recalls All Products
8. Pharmacy Robots Linked to Bacterial Contamination of Drugs
9. A Void In The Independent Pharmacy Industry Leads to Independent Rx Consulting, Powered by OurHelix
10. Second Compounding Pharmacy Shut Down in Massachusetts
11. Stress contributes to cognitive declines in women with breast cancer, researcher says
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Owner of Meningitis-Linked Pharmacy Declines to Testify Before Congress
(Date:7/27/2017)... ... July 27, 2017 , ... Trusted dentist, speaker and ... sleep apnea in Wayne, NJ to receive custom treatment at his practice ... apnea with the use of custom-crafted oral appliances. Highly-trained in using the latest ...
(Date:7/27/2017)... Viejo, CA (PRWEB) , ... July 27, 2017 , ... ... Cut Pro X . This Final Cut Pro X exclusive features transitions that contain ... and add rotation to the transition using intuitive drop-down menus. TransPanel Volume 4 makes ...
(Date:7/27/2017)... ... 2017 , ... SSCI, a division of Albany Molecular Research, ... representing a milestone achievement. , As an industry-leading provider of ... served as expert and fact witnesses to assist our clients to perform infringement ...
(Date:7/27/2017)... ... July 27, 2017 , ... MAP Health Management, ... year’s Fierce Innovation Awards: Healthcare Edition 2017, an awards program from the publisher ... Population Health Management/Patient Engagement Solutions. , MAP was selected as a finalist ...
(Date:7/27/2017)... ... July 27, 2017 , ... ... 2012-2016, will keynote Day 2 of the HIMSS Healthcare Security Forum, the nation’s ... the Sheraton Boston Hotel, Sept. 11-13, 2017. , Daniel will deliver his keynote, ...
Breaking Medicine News(10 mins):
(Date:7/26/2017)... Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced ... Altemia TM , an oral therapy for pediatric patients ... (SCD). The SCOT Trial, is a double-blind, placebo-controlled, dose-finding, ... Altemia TM in pediatric patients aged 5-17 years ... "The completion of ...
(Date:7/24/2017)... IBM (NYSE: IBM ) has been recognized ... Arrays (SSA) for the fourth year in a row. 1 ... "Vendors in the Leaders quadrant have the highest scores for ... in the Leaders quadrant has the market share, credibility, and ... new technologies. These vendors demonstrate a clear understanding of market ...
(Date:7/21/2017)... 21, 2017  Endo International plc (NASDAQ: ... review of its manufacturing network, the Company will be ... in Huntsville, Alabama . The closure ... the next 12 to 18 months. The ... volumes of commoditized products and these restructuring actions are ...
Breaking Medicine Technology: